糖尿病藥物市場規模、佔有率和成長分析（按糖尿病類型、藥物類型、最終用戶和地區分類）－2026-2033年產業預測

預計到 2024 年，全球糖尿病藥物市場規模將達到 761.1 億美元，到 2025 年將達到 813.6 億美元，到 2033 年將達到 1387.6 億美元，預測期（2026-2033 年）的複合年成長率為 6.9%。

全球糖尿病治療市場正經歷強勁成長，這主要得益於糖尿病盛行率的不斷上升、創新治療方法的進步以及醫療環境的不斷變化。人口老化帶來了巨大的市場機遇，因為老年人更容易患上糖尿病。都市化和生活方式的改變進一步增加了糖尿病的風險，從而進一步推動了市場擴張。人們對糖尿病的認知不斷提高，早期診斷也得到了廣泛應用，促進了糖尿病治療方法的普及。同時，個人化醫療的趨勢也使得量身訂製的治療方案成為可能，進而改善治療效果。人工智慧（AI）、機器學習和物聯網（IoT）等技術的整合正在革新藥物研發、病患監測和疾病管理。此外，區塊鏈技術確保了病患記錄的安全處理，從而提升了信任度和合規性。擴增實境（AR）和虛擬實境（VR）技術正被用於病患教育，幫助患者做出更健康的生活方式選擇，並提高治療依從性。

全球糖尿病藥物市場促進因素

糖尿病（包括第1型和第2型糖尿病）發生率的不斷上升，正推動著糖尿病治療市場持續成長的需求。此外，全球人口老化也加劇了這一趨勢，老年人更容易罹患糖尿病。而且，肥胖率的上升，加上久坐不動的生活方式和不健康的飲食習慣，使情況更加惡化，導致胰島素阻抗和相關代謝紊亂的增加。這些因素共同推動了糖尿病治療市場的擴張，並凸顯了開發有效治療方法以應對這一普遍存在的健康挑戰的迫切需求。

限制全球糖尿病藥物市場的因素

全球糖尿病藥物市場面臨嚴峻挑戰，因為治療第1型和第2型糖尿病的成本都非常高昂。終身治療通常需要使用胰島素、各種藥物、治療方法和血糖值監測設備，對於沒有醫療保險或醫療保障不足的人來說，這些費用可能難以負擔。這種經濟負擔，尤其是在缺乏報銷的情況下，使得許多患者難以獲得所需的糖尿病藥物。此外，新型生物製藥和個人化藥物價格的不斷上漲正在阻礙糖尿病治療領域的創新，加劇了患者和醫療服務提供者面臨的困境。

全球糖尿病藥物市場趨勢

全球糖尿病藥物市場正日益擁抱個人化和精準醫療理念，這反映了根據個人基因譜、代謝模式和生活方式因素量身定做治療方案的重要趨勢。這種轉變旨在透過解決糖尿病的根本原因並有效降低胰島素阻抗來提高治療效果。對個人化解決方案的日益重視不僅改善了患者的治療效果，也促進了以患者為中心的醫療保健環境的形成。此外，這些先進治療方法的可近性和可負擔性的提高，也促使其在不同患者群體中得到廣泛應用，從而推動了糖尿病藥物行業的持續成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管環境
• 客戶和購買標準分析
• 管道分析
• 疾病流行病學

全球糖尿病治療市場規模（依糖尿病類型及複合年成長率分類）（2026-2033 年）

• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

全球糖尿病藥物市場規模（按藥物類型和複合年成長率分類）（2026-2033 年）

• 口服降血糖藥
• 注射型抗糖尿病藥物

全球糖尿病藥物市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 個人使用

全球糖尿病治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Merck & Co.（USA）
• AstraZeneca（UK）
• Boehringer Ingelheim（Germany）
• Takeda Pharmaceutical Company（Japan）
• Johnson & Johnson（USA）
• Novartis（Switzerland）
• Bristol Myers Squibb（USA）
• Pfizer（USA）
• Roche（Switzerland）
• Bayer AG（Germany）
• AbbVie（USA）
• Daiichi Sankyo（Japan）
• Gilead Sciences（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Biocon（India）

結論與建議

Global Diabetes Therapeutics Market size was valued at USD 76.11 Billion in 2024 and is poised to grow from USD 81.36 Billion in 2025 to USD 138.76 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global diabetes therapeutics market is experiencing robust growth driven by an increasing prevalence of diabetes, innovative treatment advancements, and evolving healthcare dynamics. A rising aging population presents significant opportunities, as older individuals are more susceptible to diabetes. Urbanization and lifestyle changes further amplify diabetes risks, contributing to market expansion. Growing awareness and early diagnosis enhance the adoption of diabetes therapies, while the trend towards personalized medicine allows for tailored treatment solutions that improve efficacy. Technological integration, including AI, machine learning, and IoT, revolutionizes drug discovery, patient monitoring, and disease management. Additionally, blockchain technology ensures secure handling of patient records, fostering trust and regulatory compliance. Augmented and virtual reality are employed for patient education, supporting healthier lifestyle choices and improved treatment adherence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Therapeutics Market Segments Analysis

Global Diabetes Therapeutics Market is segmented by Diabetes Type, Drug Type, End User and region. Based on Diabetes Type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes. Based on Drug Type, the market is segmented into Oral Antidiabetics and Injectable Antidiabetics. Based on End User, the market is segmented into Hospitals, Clinics and Personal Use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetes Therapeutics Market

The growing incidence of diabetes, encompassing both type 1 and type 2, is driving sustained demand within the diabetes therapeutics market. Additionally, the increasing number of elderly individuals globally contributes to this trend, as older adults are more susceptible to developing diabetes. Furthermore, the rise in obesity rates, coupled with sedentary lifestyles and unhealthy dietary choices, exacerbates the situation, leading to higher levels of insulin resistance and related metabolic disorders. Collectively, these factors are propelling the expansion of the diabetes therapeutics market, highlighting the urgent need for effective treatment options to address this widespread health challenge.

Restraints in the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market faces considerable challenges due to the high costs associated with managing both type 1 and type 2 diabetes. Lifelong treatment often necessitates the use of insulin, various medications, therapies, and glucose monitoring devices, which can be prohibitively expensive for individuals lacking medical insurance or with inadequate healthcare coverage. This financial burden makes it difficult for many to access the necessary diabetes therapeutics, particularly in the absence of reimbursement options. Furthermore, escalating prices of novel biologics and personalized medicine are hindering innovation within the diabetes therapeutics sector, exacerbating the issues faced by patients and healthcare providers alike.

Market Trends of the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market is increasingly embracing personalized and precision medicine approaches, reflecting a significant trend towards tailored treatments that cater to individual genetic profiles, metabolic patterns, and lifestyle factors. This shift aims to address the underlying causes of diabetes, enhancing treatment efficacy by effectively reducing insulin resistance. The growing emphasis on personalized solutions not only aims to improve patient outcomes but also fosters a more patient-centric healthcare landscape. Furthermore, the increasing affordability and improved accessibility of these advanced therapies contribute to their rising popularity, facilitating broader adoption among diverse patient populations and driving sustained growth in the diabetes therapeutics sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Diabetes Therapeutics Market Size by Diabetes Type & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Therapeutics Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Oral Antidiabetics
• Injectable Antidiabetics

Global Diabetes Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Personal Use

Global Diabetes Therapeutics Market Size & CAGR (2026-2033)

• North America (Diabetes Type, Drug Type, End User)
  • US
  • Canada
• Europe (Diabetes Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diabetes Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diabetes Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diabetes Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations